deferoxamine has been researched along with Hypothyroidism in 13 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hypothyroidism: A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In 18 requiring thyroxine supplementation for hypothyroidism, 10 were able to discontinue, and four reduced their thyroxine dose." | 5.14 | Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. ( Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I, 2010) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| "Delayed puberty was present in 18." | 2.72 | Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. ( De Sanctis, V; Fortini, M; Galati, MC; Gasser, T; Raiola, G; Roos, M, 2006) |
| "Hypothyroidism is one of the common endocrine complications described in patients with β-thalassemia major (β-TM)." | 1.51 | Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with β-Thalassemia Major in Syria. ( Alquobaili, F; Kabalan, Y; Mukhalalaty, Y; Yassouf, MY, 2019) |
| "We report a case of thalassemia major with biopsy-proven pulmonary iron overload, in which thoracic high-resolution computed tomography revealed a morphological-functional correlation consistent with small airway disease." | 1.31 | Pulmonary iron overload in thalassemia major presenting as small airway disease. ( Khong, PL; Lam, WK; Ooi, GC; Trendell-Smith, NJ; Tsang, KW, 2002) |
| "Three patients had evidence of primary hypothyroidism." | 1.29 | Multiple hormone deficiencies in children with hemochromatosis. ( Cassorla, FG; Kamp, GA; Manasco, PK; Munson, PJ; Nienhuis, AW; Oerter, KE, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yassouf, MY | 1 |
| Alquobaili, F | 1 |
| Kabalan, Y | 1 |
| Mukhalalaty, Y | 1 |
| Poggi, M | 1 |
| Sorrentino, F | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| Farmaki, K | 1 |
| Tzoumari, I | 1 |
| Pappa, C | 1 |
| Chouliaras, G | 1 |
| Berdoukas, V | 1 |
| Belhoul, KM | 1 |
| Bakir, ML | 1 |
| Saned, MS | 1 |
| Kadhim, AM | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Ooi, GC | 1 |
| Khong, PL | 1 |
| Lam, WK | 1 |
| Trendell-Smith, NJ | 1 |
| Tsang, KW | 1 |
| Borgna-Pignatti, C | 1 |
| Rugolotto, S | 1 |
| De Stefano, P | 1 |
| Zhao, H | 1 |
| Cappellini, MD | 1 |
| Del Vecchio, GC | 1 |
| Romeo, MA | 1 |
| Forni, GL | 1 |
| Gamberini, MR | 1 |
| Ghilardi, R | 1 |
| Piga, A | 2 |
| Cnaan, A | 1 |
| De Sanctis, V | 2 |
| Roos, M | 1 |
| Gasser, T | 1 |
| Fortini, M | 1 |
| Raiola, G | 1 |
| Galati, MC | 1 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| Lindeman, R | 1 |
| Tuschy, U | 1 |
| Schmidt, U | 1 |
| Meinhold, J | 1 |
| Wutke, K | 1 |
| Oerter, KE | 1 |
| Kamp, GA | 1 |
| Munson, PJ | 1 |
| Nienhuis, AW | 1 |
| Cassorla, FG | 1 |
| Manasco, PK | 1 |
| Calleja, EM | 1 |
| Shen, JY | 1 |
| Lesser, M | 1 |
| Grady, RW | 1 |
| New, MI | 1 |
| Giardina, PJ | 1 |
| Gabutti, V | 1 |
| Sacchetti, L | 1 |
| Sandri, A | 1 |
| Biginelli, M | 1 |
| Saracco, P | 1 |
| Ferri, M | 1 |
| Vullo, C | 1 |
| Katz, M | 1 |
| Wonke, B | 1 |
| Hoffbrand, VA | 1 |
| Di Palma, A | 1 |
| Bagni, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for deferoxamine and Hypothyroidism
| Article | Year |
|---|---|
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxami | 2010 |
Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Body Height; Child; Child, Preschool; Deferoxamine; Female; Glu | 2006 |
11 other studies available for deferoxamine and Hypothyroidism
| Article | Year |
|---|---|
Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with β-Thalassemia Major in Syria.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Case-Control Studies; Child; Cross-Sectional Studie | 2019 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Child; Cross-Sectional Studies; Deferoxamine | 2012 |
Pulmonary iron overload in thalassemia major presenting as small airway disease.
Topics: Adult; Airway Obstruction; beta-Thalassemia; Biopsy; Chelation Therapy; Combined Modality Therapy; D | 2002 |
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe | 2004 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
[Long-term study in congenital refractory anemia and secondary siderosis].
Topics: Adolescent; Anemia, Aplastic; Deferoxamine; Dwarfism; Female; Hemosiderosis; Humans; Hypogonadism; H | 1982 |
Multiple hormone deficiencies in children with hemochromatosis.
Topics: Adolescent; Child; Deferoxamine; Endocrine System Diseases; Female; Follicle Stimulating Hormone; Go | 1993 |
Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Defero | 1998 |
Quality of life and life expectancy in thalassemic patients with complications.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Diabetes Mellitus, Type 1; Heart Diseases | 1989 |
Endocrine complications in thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Humans; Hypog | 1989 |